NCT06479291 The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
| NCT ID | NCT06479291 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yunfeng Cheng |
| Condition | Immune Thrombocytopenia With Positive ANA Antibodies |
| Study Type | INTERVENTIONAL |
| Enrollment | 126 participants |
| Start Date | 2024-07 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 126 participants in total. It began in 2024-07 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults. It will also learn about the safety of HCQ plus TPO-RA. The main questions it aims to answer are: Does HCQ plus TPO-RA raise the response rate in participants, compared to TPO-RA alone? Does HCQ plus TPO-RA prolong the response duration in participants, compared to Pred alone? Does HCQ plus TPO-RA decrease the dose of TPO-RA to maintain response in participants, compared to TPO-RA alone? What medical problems do participants have when taking HCQ plus TPO-RA? Researchers will compare HCQ plus TPO-RA with TPO-RA alone to see if HCQ plus TPO-RA works better to treat primary immune thrombocytopenia with positive anti-nuclear antibodies. Participants will: Take TPO-RA every day for no more than 24 weeks, adjust the dose of TPO-RA according to the platelet level, with or without HCQ twice a day for 1 year; Visit the clinic once every 1 weeks for the first 8 weeks, and once every 2-4 weeks in the following 10 months for checkups and tests; Keep a diary of their symptoms
Eligibility Criteria
Inclusion Criteria: 1. Age is above 15 years old. 2. Before randomization, the clinical diagnosis is primary immune thrombocytopenia. The platelet count is less than 30×10\^9 / L within 1 week before enrollment, or platelet count is less than 50×10\^9 / L with bleeding symptoms within 1 week before enrollment. 3. The antinuclear antibody is positive. 4. Other autoantibodies (mainly including dsDNA antibodies, SSA, SSB, RNP, β 2-GP, ACA, ANCA) are negative. 5. Participants who had received at least two HD-DXM 40 mg/d ×4 d, failed or relapsed, or received standard dose prednisone (1-2 mg/kg/d) for 4 weeks, the platelet count remained \<30×10 9 / L, or the platelet count normalized but decreased with prednisone tappering off, or prednisone 30mg to maintain the platelet number. 6. Prothrombin time does not exceed ± 3s of the normal value ranget, activated partial thrombin time is not outside normal range ± 10s; no history of coagulopathy except ITP. (6)Understand the study procedures and sign the written informed consent form. Exclusion Criteria: 1. Secondary thrombocytopenia caused by myelodysplastic syndrome, immune diseases such as systemic lupus erythematosus, early aplastic anemia, atypical reanemia, antiphospholipid syndrome, thrombotic thrombocytopenic purpura and various other causes. 2. The participant has experienced any arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism), or clinical symptoms and medical history indicate thrombophilia. 3. Congestive heart disease, including New York Heart Association (NHYA) Grade III / IV, occurred within 3 months prior to screening, arrhythmia requiring medication or myocardial infarction, or arrhythmia known to increase the risk of thrombotic events (such as atrial fibrillation), or corrected QT interval (QTc) is longer than 450 ms, or QTc\> 480 ms in paricipants with bundle branch block. 4. A medical history of parenchymal organ transplantation or allogeneic bone marrow transplantation. 5. Having received any medication affecting platelet function ( Including but not limited to aspirin, aspirin-containing complexes, clopidogrel, salicylates, and / or non-steroidal anti-inflammatory drugs NSAIDs ) or anticoagulant therapy for over consecutive 3 days within 2 weeks before screening. 6. With Glucose-6-phosphate dehydrogenase deficiency. 7. With retinal or visual field changes caused by 4-aminoquinoline compounds. 8. Being allergic to 4-aminoquinoline compounds. 9. Having evidence of Human Immunodeficiency Virus (HIV)/ hepatitis C virus(HCV)/ hepatitis B virus(HBV) infection (HIV antibody or HCV antibody is positive, HBV surface antigen is positive, or HBV surface antigen is negative but HBV-DNA indicating viral replication. 10. Glutamate transaminotransferase (ALT) or glutamate transaminase (AST) is higher than 1.5 times the upper limit of normal value (ULN), or total bilirubin or blood creatinine is higher than 1.2 times the ULN. 11. With liver cirrhosis or portal hypertension. 12. With evidence of malignant tumor activity, or receiving anti-tumor treatment within 5 years prior to the screening. 13. Participants being pregnant or lactating, or with potential fertility, reluctance to use effective contraception within the entire trial cycle and within 28 days after the end of the trial (or within 28 days after premature withdraw).
Contact & Investigator
Yunfeng Cheng
PRINCIPAL INVESTIGATOR
Shanghai Zhongshan Hospital
Frequently Asked Questions
Who can join the NCT06479291 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 99 Years, studying Immune Thrombocytopenia With Positive ANA Antibodies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06479291 currently recruiting?
Yes, NCT06479291 is actively recruiting participants. Contact the research team at ji.lili@zs-hospital.sh.cn for enrollment information.
Where is the NCT06479291 trial being conducted?
This trial is being conducted at Shanghai, China, Shanghai, China, Shanghai, China, Shanghai, China and 3 additional locations.
Who is sponsoring the NCT06479291 clinical trial?
NCT06479291 is sponsored by Yunfeng Cheng. The principal investigator is Yunfeng Cheng at Shanghai Zhongshan Hospital. The trial plans to enroll 126 participants.